The effects of Herkinorin, the first μ-selective ligand from a salvinorin a-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primates

Eduardo R. Butelman, Szymon Rus, Denise S. Simpson, Angela Wolf, Thomas E. Prisinzano, Mary Jeanne Kreek

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Herkinorin is the first μ-opioid receptor-selective ligand from the salvinorin A diterpenoid scaffold. Herkinorin has relative μ > κ > δ binding selectivity, and it can act as an agonist at both μ- and κ-receptors, in vitro. These studies were the first in vivo evaluation of the effects of herkinorin in nonhuman primates, using prolactin release, a neuroendocrine biomarker assay that is responsive to both μ- and κ-agonists, as well as to compounds with limited ability to cross the blood-brain barrier. In cumulative dosing studies (0.01-0.32 mg/kg i.v.), herkinorin produced only small effects in gonadally intact males (n = 4), but a more robust effect in females (n = 4). Time course studies with herkinorin (0.32 mg/kg) confirmed this greater effectiveness in females and revealed a fast onset after i.v. administration (e.g., by 5-15 min). Antagonism experiments with different doses of nalmefene (0.01 and 0.1 mg/kg) caused dose-dependent and complete prevention of the effect of herkinorin in females. This is consistent with a principal μ-agonist effect of herkinorin, with likely partial contribution by κ-agonist effects. The peripherally selective antagonist quaternary naltrexone (1 mg/kg s.c.) caused approximately 70% reduction in the peak effect of herkinorin (0.32 mg/kg) in females, indicating that this effect of herkinorin is prominently mediated outside the blood-brain barrier.

Original languageEnglish
Pages (from-to)154-160
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume327
Issue number1
DOIs
StatePublished - Oct 2008

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Fingerprint

Dive into the research topics of 'The effects of Herkinorin, the first μ-selective ligand from a salvinorin a-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primates'. Together they form a unique fingerprint.

Cite this